Prednisone for the prevention of paradoxical tuberculosis-associated IRIS. Meintjes, G. A, Stek, C., Blumenthal, L., Thienemann, F., Schutz, C., Buyze, J., Ravinetto, R., van Loen, H., Nair, A., Jackson, A., Colebunders, R., Maartens, G., Wilkinson, R. J, & Lynen, L. New England Journal of Medicine, 379(20):1915–1925, Massachusetts Medical Society, nov, 2018. ![Prednisone for the prevention of paradoxical tuberculosis-associated IRIS [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex Abstract Background Early initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)–infected patients who have tuberculosis reduces mortality among patients with low CD4 counts, but it increases the risk of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS). Methods We conducted this randomized, double-blind, placebo-controlled trial to assess whether prophylactic prednisone can safely reduce the incidence of paradoxical tuberculosis-associated IRIS in patients at high risk for the syndrome. We enrolled HIV-infected patients who were initiating ART (and had not previously received ART), had started tuberculosis treatment within 30 days before initiating ART, and had a CD4 count of 100 cells or fewer per microliter. Patients received either prednisone (at a dose of 40 mg per day for 14 days, then 20 mg per day for 14 days) or placebo. The primary end point was the development of tuberculosis-associated IRIS within 12 weeks after initiating ART, as ...
@article{Meintjes2018,
abstract = {Abstract Background Early initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)–infected patients who have tuberculosis reduces mortality among patients with low CD4 counts, but it increases the risk of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS). Methods We conducted this randomized, double-blind, placebo-controlled trial to assess whether prophylactic prednisone can safely reduce the incidence of paradoxical tuberculosis-associated IRIS in patients at high risk for the syndrome. We enrolled HIV-infected patients who were initiating ART (and had not previously received ART), had started tuberculosis treatment within 30 days before initiating ART, and had a CD4 count of 100 cells or fewer per microliter. Patients received either prednisone (at a dose of 40 mg per day for 14 days, then 20 mg per day for 14 days) or placebo. The primary end point was the development of tuberculosis-associated IRIS within 12 weeks after initiating ART, as ...},
author = {Meintjes, Graeme A and Stek, Cari and Blumenthal, Lisette and Thienemann, Friedrich and Schutz, Charlotte and Buyze, Jozefien and Ravinetto, Raffaella and van Loen, Harry and Nair, Amy and Jackson, Amanda and Colebunders, Robert and Maartens, Gary and Wilkinson, Robert J and Lynen, Lutgarde},
doi = {10.1056/NEJMoa1800762},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Meintjes et al. - 2018 - Prednisone for the prevention of paradoxical tuberculosis-associated IRIS.pdf:pdf},
journal = {New England Journal of Medicine},
keywords = {OA,fund{\_}ack,original},
mendeley-tags = {OA,fund{\_}ack,original},
month = {nov},
number = {20},
pages = {1915--1925},
pmid = {30428290},
publisher = {Massachusetts Medical Society},
title = {{Prednisone for the prevention of paradoxical tuberculosis-associated IRIS}},
url = {http://www.nejm.org/doi/10.1056/NEJMoa1800762},
volume = {379},
year = {2018}
}
Downloads: 0
{"_id":"x4fjbq5iGfzkevM3F","bibbaseid":"meintjes-stek-blumenthal-thienemann-schutz-buyze-ravinetto-vanloen-etal-prednisoneforthepreventionofparadoxicaltuberculosisassociatediris-2018","author_short":["Meintjes, G. A","Stek, C.","Blumenthal, L.","Thienemann, F.","Schutz, C.","Buyze, J.","Ravinetto, R.","van Loen, H.","Nair, A.","Jackson, A.","Colebunders, R.","Maartens, G.","Wilkinson, R. J","Lynen, L."],"bibdata":{"bibtype":"article","type":"article","abstract":"Abstract Background Early initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)–infected patients who have tuberculosis reduces mortality among patients with low CD4 counts, but it increases the risk of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS). Methods We conducted this randomized, double-blind, placebo-controlled trial to assess whether prophylactic prednisone can safely reduce the incidence of paradoxical tuberculosis-associated IRIS in patients at high risk for the syndrome. We enrolled HIV-infected patients who were initiating ART (and had not previously received ART), had started tuberculosis treatment within 30 days before initiating ART, and had a CD4 count of 100 cells or fewer per microliter. Patients received either prednisone (at a dose of 40 mg per day for 14 days, then 20 mg per day for 14 days) or placebo. The primary end point was the development of tuberculosis-associated IRIS within 12 weeks after initiating ART, as ...","author":[{"propositions":[],"lastnames":["Meintjes"],"firstnames":["Graeme","A"],"suffixes":[]},{"propositions":[],"lastnames":["Stek"],"firstnames":["Cari"],"suffixes":[]},{"propositions":[],"lastnames":["Blumenthal"],"firstnames":["Lisette"],"suffixes":[]},{"propositions":[],"lastnames":["Thienemann"],"firstnames":["Friedrich"],"suffixes":[]},{"propositions":[],"lastnames":["Schutz"],"firstnames":["Charlotte"],"suffixes":[]},{"propositions":[],"lastnames":["Buyze"],"firstnames":["Jozefien"],"suffixes":[]},{"propositions":[],"lastnames":["Ravinetto"],"firstnames":["Raffaella"],"suffixes":[]},{"propositions":["van"],"lastnames":["Loen"],"firstnames":["Harry"],"suffixes":[]},{"propositions":[],"lastnames":["Nair"],"firstnames":["Amy"],"suffixes":[]},{"propositions":[],"lastnames":["Jackson"],"firstnames":["Amanda"],"suffixes":[]},{"propositions":[],"lastnames":["Colebunders"],"firstnames":["Robert"],"suffixes":[]},{"propositions":[],"lastnames":["Maartens"],"firstnames":["Gary"],"suffixes":[]},{"propositions":[],"lastnames":["Wilkinson"],"firstnames":["Robert","J"],"suffixes":[]},{"propositions":[],"lastnames":["Lynen"],"firstnames":["Lutgarde"],"suffixes":[]}],"doi":"10.1056/NEJMoa1800762","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Meintjes et al. - 2018 - Prednisone for the prevention of paradoxical tuberculosis-associated IRIS.pdf:pdf","journal":"New England Journal of Medicine","keywords":"OA,fund_ack,original","mendeley-tags":"OA,fund_ack,original","month":"nov","number":"20","pages":"1915–1925","pmid":"30428290","publisher":"Massachusetts Medical Society","title":"Prednisone for the prevention of paradoxical tuberculosis-associated IRIS","url":"http://www.nejm.org/doi/10.1056/NEJMoa1800762","volume":"379","year":"2018","bibtex":"@article{Meintjes2018,\r\nabstract = {Abstract Background Early initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)–infected patients who have tuberculosis reduces mortality among patients with low CD4 counts, but it increases the risk of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS). Methods We conducted this randomized, double-blind, placebo-controlled trial to assess whether prophylactic prednisone can safely reduce the incidence of paradoxical tuberculosis-associated IRIS in patients at high risk for the syndrome. We enrolled HIV-infected patients who were initiating ART (and had not previously received ART), had started tuberculosis treatment within 30 days before initiating ART, and had a CD4 count of 100 cells or fewer per microliter. Patients received either prednisone (at a dose of 40 mg per day for 14 days, then 20 mg per day for 14 days) or placebo. The primary end point was the development of tuberculosis-associated IRIS within 12 weeks after initiating ART, as ...},\r\nauthor = {Meintjes, Graeme A and Stek, Cari and Blumenthal, Lisette and Thienemann, Friedrich and Schutz, Charlotte and Buyze, Jozefien and Ravinetto, Raffaella and van Loen, Harry and Nair, Amy and Jackson, Amanda and Colebunders, Robert and Maartens, Gary and Wilkinson, Robert J and Lynen, Lutgarde},\r\ndoi = {10.1056/NEJMoa1800762},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Meintjes et al. - 2018 - Prednisone for the prevention of paradoxical tuberculosis-associated IRIS.pdf:pdf},\r\njournal = {New England Journal of Medicine},\r\nkeywords = {OA,fund{\\_}ack,original},\r\nmendeley-tags = {OA,fund{\\_}ack,original},\r\nmonth = {nov},\r\nnumber = {20},\r\npages = {1915--1925},\r\npmid = {30428290},\r\npublisher = {Massachusetts Medical Society},\r\ntitle = {{Prednisone for the prevention of paradoxical tuberculosis-associated IRIS}},\r\nurl = {http://www.nejm.org/doi/10.1056/NEJMoa1800762},\r\nvolume = {379},\r\nyear = {2018}\r\n}\r\n","author_short":["Meintjes, G. A","Stek, C.","Blumenthal, L.","Thienemann, F.","Schutz, C.","Buyze, J.","Ravinetto, R.","van Loen, H.","Nair, A.","Jackson, A.","Colebunders, R.","Maartens, G.","Wilkinson, R. J","Lynen, L."],"key":"Meintjes2018","id":"Meintjes2018","bibbaseid":"meintjes-stek-blumenthal-thienemann-schutz-buyze-ravinetto-vanloen-etal-prednisoneforthepreventionofparadoxicaltuberculosisassociatediris-2018","role":"author","urls":{"Paper":"http://www.nejm.org/doi/10.1056/NEJMoa1800762"},"keyword":["OA","fund_ack","original"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["oa","fund_ack","original"],"search_terms":["prednisone","prevention","paradoxical","tuberculosis","associated","iris","meintjes","stek","blumenthal","thienemann","schutz","buyze","ravinetto","van loen","nair","jackson","colebunders","maartens","wilkinson","lynen"],"title":"Prednisone for the prevention of paradoxical tuberculosis-associated IRIS","year":2018}